Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    AZD5634
Previous Study | Return to List | Next Study

A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02950805
Recruitment Status : Completed
First Posted : November 1, 2016
Last Update Posted : July 13, 2018
Sponsor:
Collaborator:
Parexel
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This study will assess the effect of inhaled AZD5634 on Mucociliary clearance (MCC) in patients with Cystic fibrosis (CF) after single-dose administration.

Condition or disease Intervention/treatment Phase
Pulmonary/Respiratory Diseases Drug: Placebo Drug: AZD5634 Phase 1

Detailed Description:
The primary pharmacodynamic endpoint will be the average whole lung particle clearance between 0 and 60 minutes after administration of aerosolized radiolabelled particles (colloids) at Visits 2 and 3 (%MCC 0-60, whole).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1b Randomized Blinded Placebo-Controlled, Cross-Over Study to Assess the Effect of AZD5634 on Mucociliary Clearance as Well as Safety, Tolerability, and Pharmacokinetic Parameters Following Single Inhaled Dose Administration to Patients With Cystic Fibrosis.
Actual Study Start Date : May 30, 2017
Actual Primary Completion Date : April 12, 2018
Actual Study Completion Date : April 12, 2018


Arm Intervention/treatment
Experimental: Placebo + AZD5634
Subjects were administered single dose of placebo in period 1 and AZD5634 in period 2.
Drug: Placebo
Subjects will receive a placebo in either period 1 or period 2 by inhalation.

Drug: AZD5634
Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.

Experimental: AZD5634 + Placebo
Subjects were administered single dose of AZD5634 in period 1 and placebo in period 2.
Drug: Placebo
Subjects will receive a placebo in either period 1 or period 2 by inhalation.

Drug: AZD5634
Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.




Primary Outcome Measures :
  1. Percentage of average whole lung particle clearance between 0 and 60 minutes after administration of aerosolized radiolabelled particles [ Time Frame: 0 to 60 minutes ]
    Assessment of the average whole lung clearance between 0 and 60 minutes after administration of single inhaled dose of aerosolized radiolabelled particles (colloids) of AZD5634, (%MCC 0--60, whole) in subjects with cystic fibrosis (CF).


Secondary Outcome Measures :
  1. Percentage of average central clearance between 0 and 60 minutes after administration of aerosolized radiolabelled particles [ Time Frame: 0 to 60 minutes ]
    Assessment and comparison of the average central clearance between 0 and 60 minutes after administration of single inhaled dose of aerosolized radiolabelled particles (colloids) of AZD5634, in subjects with CF.

  2. Percentage of average peripheral clearance between 0 and 60 minutes after administration of aerosolized radiolabelled particles [ Time Frame: 0 to 60 minutes ]
    Assessment and comparison of the average peripheral clearance between 0 and 60 minutes after administration of single inhaled dose of aerosolized radiolabelled particles (colloids) of AZD5634 in subjects with CF.

  3. Percentage of average tracheobronchial clearance between 0 and 60 minutes after administration of aerosolized radiolabelled particles [ Time Frame: 0 to 60 minutes ]
    Assessment and comparison of the average tracheobronchial clearance between 0 and 60 minutes after administration of single inhaled dose of aerosolized radiolabelled particles (colloids) of AZD5634 in subjects with CF.

  4. Percentage of particle clearance at 6-hour [ Time Frame: 6 hours ]
    Assessment and comparison the 6-hour clearance after administration of aerosolized radiolabelled particles (colloids) of AZD5634 in subjects with CF.

  5. Percentage of average whole lung cough clearance between 60 minutes and 90 minutes after administration of aerosolized radiolabelled particles [ Time Frame: 60 minutes to 90 minutes ]
    Assessment of the average whole lung cough clearance between 60 minutes and 90 minutes after administration of single inhaled dose of aerosolized radiolabelled particles (colloids) of AZD5634 in subjects with CF.

  6. Percentage of average central cough clearance between 60 minutes and 90 minutes after administration of aerosolized radiolabelled particles [ Time Frame: 60 minutes to 90 minutes ]
    Assessment and comparison of the average central cough clearance between 60 minutes and 90 minutes after administration of single inhaled dose of aerosolized radiolabelled particles (colloids) of AZD5634 in subjects with CF.

  7. Percentage of average peripheral cough clearance between 60 minutes and 90 minutes after administration of aerosolized radiolabelled particles [ Time Frame: 60 minutes to 90 minutes ]
    Assessment and comparison of the average peripheral cough clearance between 60 minutes and 90 minutes after administration of single inhaled dose of aerosolized radiolabelled particles (colloids) of AZD5634 in subjects with CF.

  8. Percentage of average tracheobronchial cough clearance between 60 minutes and 90 minutes after administration of aerosolized radiolabelled particles [ Time Frame: 60 minutes to 90 minutes ]
    Assessment and comparison of the average tracheobronchial cough clearance between 60 minutes and 90 minutes after administration of single inhaled dose of aerosolized radiolabelled particles (colloids) of AZD5634 in subjects with CF.

  9. Maximum observed plasma concentration (Cmax) [ Time Frame: Pre-dose and up to 6 hours post-dose ]
    Assessment of Cmax in subjects with CF after the administration of single inhaled dose of AZD5634.

  10. Area under the concentration-time curve from time zero extrapolated to infinity (AUC) [ Time Frame: Pre-dose and up to 6 hours post-dose ]
    Assessment of AUC in subjects with CF after the administration of single inhaled dose of AZD5634.

  11. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC 0-last) [ Time Frame: Pre-dose and up to 6 hours post-dose ]
    Assessment of AUC 0-last in subjects with CF after the administration of single inhaled dose of AZD5634.

  12. Area under the plasma concentration-time curve from time zero to 6 hours post-dose (AUC 0-6) [ Time Frame: Pre-dose and up to 6 hours post-dose ]
    Assessment of AUC 0-6 in subjects with CF after the administration of single inhaled dose of AZD5634.

  13. Observed last quantifiable concentration (C last) [ Time Frame: Pre-dose and up to 6 hours post-dose ]
    Assessment of C last in subjects with CF after the administration of single inhaled dose of AZD5634.

  14. Time of last quantifiable concentration (t last) [ Time Frame: Pre-dose and up to 6 hours post-dose ]
    Assessment of t last in subjects with CF after the administration of single inhaled dose of AZD5634.

  15. Time to reach maximum plasma concentration (t max) [ Time Frame: Pre-dose and up to 6 hours post-dose ]
    Assessment of t max in subjects with CF after the administration of single inhaled dose of AZD5634.

  16. Terminal elimination rate constant (λz) [ Time Frame: Pre-dose and up to 6 hours post-dose ]
    Assessment of λz in subjects with CF after the administration of single inhaled dose of AZD5634.

  17. Terminal elimination half-life (t1/2,λz) [ Time Frame: Pre-dose and up to 6 hours post-dose ]
    Assessment of t1/2,λz in subjects with CF after the administration of single inhaled dose of AZD5634.

  18. Apparent clearance (CL/F) [ Time Frame: Pre-dose and up to 6 hours post-dose ]
    Assessment of CL/F in subjects with CF after the administration of single inhaled dose of AZD5634.

  19. Apparent volume of distribution at terminal phase (Vz/F) [ Time Frame: Pre-dose and up to 6 hours post-dose ]
    Assessment of Vz/F in subjects with CF after the administration of single inhaled dose of AZD5634.

  20. Cumulative amount of AZD5634 excreted in urine from time zero to 6 hours (Ae 0-6) [ Time Frame: Pre-dose and up to 6 hours post-dose ]
    Assessment of Ae 0-6 in subjects with CF after the administration of single inhaled dose of AZD5634.

  21. Cumulative percentage of dose excreted unchanged in urine from time zero to 6 hours (fe(0-6)%) [ Time Frame: Pre-dose and up to 6 hours post-dose ]
    Assessment of fe(0-6)% in subjects with CF after the administration of single inhaled dose of AZD5634.

  22. Renal clearance, estimated by dividing Ae(0-t) (CLR) [ Time Frame: Pre-dose and up to 6 hours post-dose ]

    Assessment of CLR in subjects with CF after the administration of single inhaled dose of AZD5634.

    CLR is defined as renal clearance, estimated by dividing Ae(0-t) cumulative amount of AZD5634 excreted in urine from time zero up to time t) by AUC 0-t (area under the plasma concentration-time curve from time zero to time t), where t represents a matching time point for plasma and urine sampling.


  23. Safety of subjects by evaluating the incidence of adverse events (AEs) [ Time Frame: From screening (≤28 days) up to 14-21 days post dosing ]
    Assessment of the safety in terms of the incidences of the AEs after the administration of single inhaled dose of AZD5634 in subjects with CF.

  24. Safety of subjects by evaluating the systolic and diastolic blood pressure [ Time Frame: From screening (≤28 days) up to 14-21 days post dosing ]
    Assessment of the safety in terms of systolic and diastolic blood pressure after the administration of single inhaled dose of AZD5634 in subjects with CF.

  25. Safety of subjects by evaluating the pulse rate. [ Time Frame: From screening (≤28 days) up to 14-21 days post dosing ]
    Assessment of the safety in terms of pulse rate after the administration of single inhaled dose of AZD5634 in subjects with CF.

  26. Safety of subjects by evaluating spirometry results [ Time Frame: From screening (≤28 days) up to 14-21 days post dosing ]
    Assessment of the safety by evaluating the spirometry results after administration of the of single inhaled dose of AZD5634 in subjects with CF.

  27. Safety of subjects by evaluating the ECG results [ Time Frame: Pre-dose and up to 6 hours post-dose ]
    Assessment of the safety by evaluating the ECG results after administration of the of single inhaled dose of AZD5634 in subjects with CF.

  28. Safety of subjects by the physical examination [ Time Frame: From screening (≤28 days) up to 14-21 days post dosing ]
    Assessment of the safety by physical examination after administration of the of single inhaled dose of AZD5634 in subjects with CF.

  29. Safety of subjects by evaluating the respiratory rate. [ Time Frame: From screening (≤28 days) up to 14-21 days post dosing ]
    Assessment of the safety in terms of respiratory rate after the administration of single inhaled dose of AZD5634 in subjects with CF.

  30. Safety of subjects by evaluating fractional excretion of potassium (FEK) [ Time Frame: Pre-dose and at 0-6 hours post-dose ]
    Assessment of FEK after the administration of single inhaled dose of AZD5634 in subjects with CF.

  31. Safety of subjects by evaluating urine sodium/potassium (Na/K) ratio [ Time Frame: Pre-dose and at 0-6 hours post-dose ]
    Assessment of ratio of Na/K after the administration of single inhaled dose of AZD5634 in subjects with CF.

  32. Safety of subjects by evaluating the pulse oximetry [ Time Frame: From screening (≤28 days) up to 14-21 days post dosing ]
    Assessment of the safety in terms of pulse rate after the administration of single inhaled dose of AZD5634 in subjects with CF.

  33. Safety of subjects by evaluating the clinical laboratory test results for biochemistry [ Time Frame: From screening (≤28 days) until 14-21 days post dosing ]
    Assessment of the clinical laboratory test results in terms of biochemistry after the administration of single inhaled dose of AZD5634 in subjects with CF.

  34. Safety of subjects by evaluating the clinical laboratory test results for urinalysis [ Time Frame: From screening (≤28 days) until 14-21 days post dosing ]
    Assessment of the clinical laboratory test results in terms of urinalysis after the administration of single inhaled dose of AZD5634 in subjects with CF.

  35. Safety of subjects by evaluating the clinical laboratory test results for hematology [ Time Frame: From screening (≤28 days) until 14-21 days post dosing ]
    Assessment of the clinical laboratory test results in terms of hematology after the administration of single inhaled dose of AZD5634 in subjects with CF.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provision of signed and dated written informed consent prior to any study-specific procedures.
  2. Male or female patients aged 18-60 years old inclusive.
  3. Diagnosed of CF at Screening as evidenced in medical records by one of the following criteria:

    1. sweat chloride ≥ 60 mmol/L
    2. presence of 2 mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.
  4. Chronic sinopulmonary disease or pancreatic insufficiency.
  5. FEV1measurement at Screening ≥ 40% of the predicted normal value of age, height, gender, and race.
  6. Stable CF regimen for at least 2 months before Screening.
  7. Body mass index (BMI) between 15-30 kg/m2 inclusive.
  8. Female patients are not pregnant and do not plan to become pregnant during the study, are not lactating, or are of non-childbearing potential. Females of childbearing potential must provide a negative serum pregnancy test and have a date of last menstruation consistent with non-pregnancy, negative urine pregnancy tests at each visit, and must be using at least one highly effective method of contraception.
  9. Ability of the patient to correctly perform the inhalation procedure after training during the Screening Visit.

Exclusion Criteria:

  1. Had a pulmonary exacerbation requiring change in antibiotics and/or hospitalization within 28 days before the first dose of Investigational product.
  2. History of lung transplant or any other transplantation.
  3. Currently being treated with ivacaftor monotherapy at Screening or received ivacaftor monotherapy within 30 days before Screening.
  4. History of severe allergy/hypersensitivity or ongoing clinically significant allergy/hypersensitivity, as judged by the Investigator, to drugs in a similar class to AZD5634.
  5. History or presence of hepatic cirrhosis.
  6. Creatinine clearance <60 mL/min/m2 using the Cockroft-Gault Equation.
  7. Liver function test results >2x upper limit of normal (aspartate aminotransferase [AST], alanine aminotransferase [ALT], gamma-glutamyl transpeptidase [GGT], or bilirubin)
  8. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study.
  9. Received treatment with the following medications within the 3 weeks before Screening: strong or moderate Cytochrome P450 (CYP) 3A inhibitors, as classified by the Food and Drug Administration (FDA).
  10. Likely to require treatment during the study with drugs not permitted by the study protocol.
  11. Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results.
  12. Serum potassium levels are outside the normal range (3.5-5.1 mmol/L).
  13. Serum sodium levels <135 mmol/L.
  14. Abnormal vital signs, after 5 minutes rest, at Screening or Visit 2 (seated or supine; position should be consistent for a given patient at both visits), defined as any of the following:

    • Systolic blood pressure (B.P) < 90 or ≥ 150 mmHg
    • Diastolic B.P < 45 or ≥ 90 mmHg
    • Pulse rate < 45 or >110 beats/minute
  15. Any clinically significant abnormalities in rhythm, conduction, or morphology of the resting ECG and any clinically significant abnormalities in the 12-lead ECG, as considered by the Investigator, that may interfere with the interpretation of corrected ECG interval measured from the onset of the QRS complex to the offset of the T wave (QTc) interval changes.
  16. QTc prolongation defined as QT interval corrected for heart rate using Fridericia's formula (QTcF) >450 ms.
  17. ECG interval measured from the onset of the P wave to the onset of the QRS complex (PR/PQ) interval prolongation (>240 ms), intermittent second or third degree atrioventricular (AV) block, or AV dissociation.
  18. Persistent or intermittent complete bundle branch block (BBB) with ECG interval measured from the onset of the QRS complex to the J point (QRS) >120 ms or evidence of pre-excitation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02950805


Locations
Layout table for location information
United States, Alabama
Research Site
Birmingham, Alabama, United States, 35294-1785
United States, Maryland
Research Site
Baltimore, Maryland, United States, 21205
United States, North Carolina
Research Site
Chapel Hill, North Carolina, United States, 27517
Sponsors and Collaborators
AstraZeneca
Parexel
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02950805    
Other Study ID Numbers: D6600C00002
First Posted: November 1, 2016    Key Record Dates
Last Update Posted: July 13, 2018
Last Verified: July 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
AZD5634
Mucociliary Clearance
Safety
Tolerability
Pharmacokinetic
Cystic Fibrosis
Cross-Over Study
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Respiration Disorders
Respiratory Tract Diseases
Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases